Inhibitors of squalene synthase and protein farnesyltransferase
申请人:Abbott Laboratories
公开号:US05831115A1
公开(公告)日:1998-11-03
The present invention provides a compound of the formula ##STR1## or a pharmaceutically acceptable salt thereof, which are useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
Inhibitors of squalene synthetase and protein farnesyltransferase
申请人:Abbott Laboratories
公开号:US05783593A1
公开(公告)日:1998-07-21
The present invention provides a compound of the formula ##STR1## which inhibit squalene synthetase and cholesterol biosynthesis and are useful in the treatment of e.g., hyperlipidaemia, atherosclerosis, or fungal infections, processes for the preparation of the compounds of the invention, intermediates useful in these processes, and pharmaceutical compositions containing the compounds.
[EN] BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE<br/>[FR] DERIVES DE BENZENE, PYRIDINE, NAPHTALENE OU BENZOPHENONE UTILISES COMME INHIBITEURS DE LA SQUALENE SYNTHETASE ET DE LA PROTEINE FARNESYLTRANSFERASE
申请人:ABBOTT LABORATORIES
公开号:WO1996034851A1
公开(公告)日:1996-11-07
(EN) The present invention provides a compound of formula (I), (II), (III) or (IV), processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and methods of using the compounds of the invention.(FR) La présente invention se rapporte à des composés de la formule (I), (II), (III) ou (IV), aux procédés de préparation de ces composés, aux intermédiaires utilisés dans ces procédés, à une composition pharmaceutique et aux procédés d'utilisation de ces composés.
Cyclobutane derivatives as inhibitors of protein farnesyltransferase
申请人:ABBOTT LABORATORIES
公开号:EP1090908A2
公开(公告)日:2001-04-11
The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
本发明提供了一种可用于抑制蛋白法尼基转移酶和癌基因蛋白 Ras 的法尼基化的式 (II) 化合物或其药学上可接受的盐,还提供了制备本发明化合物的工艺以及在这些工艺中有用的中间体、药物组合物和使用这些化合物的方法。
Discovery of Novel <i>p</i>-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead
作者:Gang Liu、J. T. Link、Zhonghua Pei、Edward B. Reilly、Sandra Leitza、Bach Nguyen、Kennan C. Marsh、Gregory F. Okasinski、Thomas W. von Geldern、Mark Ormes、Kerry Fowler、Mike Gallatin
DOI:10.1021/jm0002782
日期:2000.10.1
The interaction between leukocyte function-associated antigen-1 (LFA-1), a member of the beta (2)-integrin family of adhesion molecules, and intracellular adhesion molecule ICAM-1 (cd54) is thought to play a critical role in the inflammatory process. On the basis of an anilino diaryl sulfide screening lead 1, in combination with pharmacophore analysis of other screening hits, we have identified an adjacent binding pocket. Subsequently, a p-ethenylcarbonyl linker was discovered to be optimal for accessing this binding site. Solution-phase parallel synthesis enabled rapid optimization of the cinnamides for this pocket. In conjunction with fine-tuning of the diaryl substituents, we discovered a novel series of potent, nonpeptide inhibitors of LFA-1/ICAM-1 interaction, exemplified by A-286982 (28h), which has IC50 values of 44 and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-l-mediated cellular adhesion assay, respectively.